Absci and Kennedy Institute partner to expedite immunotherapies development

12 May 2023
www.pharmaceutical-technology.com
Immunotherapy
Absci and Kennedy Institute partner to expedite immunotherapies development
Preview
Source: Pharmaceutical Technology
The collaboration intends to expedite the development of therapies for immune-mediated diseases. Credit: fernando zhiminaicela från Pixabay.
Absci has collaborated with the University of Oxford’s Kennedy Institute of Rheumatology to expedite the development of AI-driven immunotherapies.
The collaboration will use the integrated drug creation platform of Absci and the clinical immunology datasets from the Kennedy Institute to identify antibodies to immune-mediated inflammatory diseases and autoimmune conditions with unprecedented speed.
Recommended Reports
Absci and Kennedy Institute partner to expedite immunotherapies development
Preview
Source: Pharmaceutical Technology
ReportsVirion Infectivity Factor (SOR Protein or vif) Drugs in Development by Therapy Areas and Indicati... GlobalData
Absci and Kennedy Institute partner to expedite immunotherapies development
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Imiglucerase Biosimilar in Gaucher Disease GlobalData
View all
Absci will utilise the generative AI models with genomics datasets from the Kennedy Institute to identify new antibodies from patients with immune responses to inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease.
The company will then reassemble the antigen-antibody pairs, using its reverse immunology approach, as starting points for the development of drugs.
Absci founder and CEO Sean McClain stated: “The Kennedy Institute’s vast, high-quality biorepository data expand Absci’s strategic research and development portfolio and aim to unlock major advances for a range of immune-mediated conditions that millions suffer from.
“Together with our established data partnerships with St. John’s Cancer Institute and Aster Insights, this partnership gives Absci a robust data pipeline that enables our AI platform across a wide range of therapeutic areas as we build our internal therapeutic pipeline.”
The company’s integrated drug creation platform combines data, AI and wet-lab capabilities for screening several cells per week.
This allows the platform to move from AI-designed antibodies to lab-validated candidates in as little as six weeks.
The Kennedy Institute clinical research director Christopher Buckley stated: “Absci’s reverse immunology approach promises to turn clinical data into pharmaceutical drugs.
“We are excited about the potential for generative AI to accelerate the discovery of promising drug candidates and better understand their potential efficacy and safety profiles.
“This partnership will help accelerate our findings in the clinic into new immunotherapies for patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.